Skip to main content

Table 1 Clinical characteristics of 20 R/R B-ALL patients

From: Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia

Patient number Age Gender ECOG Leukemia type and genetic abnormalities Disease status BM blasts burden Prior lines of treatment EMD status
1 31 Female 1 Ph-ALL Refractory 56.0% 2 No
2 23 Female 1 Ph+ALL*(T315I mutation) Relapse 38.6% 2 No
3 50 Male 0 Ph-ALL Refractory 3.0% 2 No
4 18 Male 0 Ph-ALL Relapse 30.5% 2 No
5 44 Male 0 Ph-ALL Refractory 24.5% 2 No
6 16 Male 0 Ph-ALL (IKZF1 deletion, NRAS mutation) Refractory 26.0% 3 No
7 10 Male 0 Ph-ALL (E2A-PBX1 rearrangement) Relapse 4.5% 2 No
8 16 Male 0 Ph+ALL (T315I mutation) Relapse 83.5% 2 No
9 24 Male 1 Ph-ALL Relapse 40.5% 2 No
10 9 Male 0 Ph-ALL (IgH rearrangements) Refractory 40.5% 2 No
11 7 Male 0 Ph-ALL Relapse 7.5% 2 No
12 9 Female 0 Ph-ALL (ETV6-RUNX1 rearrangement) Relapse 10.0% 2 No
13 19 Male 0 Ph-like ALL (EBF1-PDGFRB rearrangement, IKZF1 deletion) Relapse 75.0% 2 Yes
14 14 Female 0 Ph-ALL Refractory 32.5% 3 No
15 18 Male 0 Ph-like ALL (PAX5-JAK2 rearrangement, TP53 deletion) Relapse 73.5% 1 No
16 43 Female 1 Ph-ALL Refractory 60.5% 2 No
17 11 Female 0 Ph-ALL Refractory 5.0% 2 No
18 3 Female 0 Ph-ALL (TP53 mutation, IKZF1 deletion) Refractory 6.0% 5 No
19 52 Female 0 Ph-ALL Refractory 96.0% 2 No
20 40 Male 0 Ph-ALL (IKZF1 deletion) Refractory 64.5% 2 Yes
  1. EMD extramedullary disease, Ph Philadelphia chromosome